Novel Immunotherapeutic Approaches for Neuroblastoma and Malignant Melanoma

Research output: Contribution to journalReview article

Abstract

Neuroblastoma (NB) and malignant melanoma (MM), tumors of pediatric age and adulthood, respectively, share a common origin, both of them deriving from the neural crest cells. Although NB and MM have a different behavior, in respect to age of onset, primary tissue involvement and metastatic spread, the prognosis for high stage-affected patients is still poor, in spite of aggressive treatment strategies and the huge amount of new discovered biological knowledge. For these reasons researchers are continuously attempting to find out new treatment options, which in a near future could be translated to the clinical practice. In the last two decades, a strong effort has been spent in the field of translational research of immunotherapy which led to satisfactory results. Indeed, several immunotherapeutic clinical trials have been performed and some of them also resulted beneficial. Here, we summarize preclinical studies based on immunotherapeutic approaches applied in models of both NB and MM.

Original languageEnglish
Pages (from-to)8097398
JournalJournal of Immunology Research
Volume2018
DOIs
Publication statusPublished - 2018

Fingerprint

Neuroblastoma
Melanoma
Translational Medical Research
Neural Crest
Age of Onset
Immunotherapy
Research Personnel
Clinical Trials
Pediatrics
Therapeutics
Neoplasms

Keywords

  • Adult
  • Animals
  • Antineoplastic Combined Chemotherapy Protocols/therapeutic use
  • Child
  • Clinical Trials as Topic
  • Disease Models, Animal
  • Drug Evaluation, Preclinical
  • Humans
  • Immunotherapy/methods
  • Melanoma/immunology
  • Neural Crest/pathology
  • Neuroblastoma/immunology
  • Remission Induction
  • Translational Medical Research

Cite this

@article{2861965eaca8428790003e57eab14c87,
title = "Novel Immunotherapeutic Approaches for Neuroblastoma and Malignant Melanoma",
abstract = "Neuroblastoma (NB) and malignant melanoma (MM), tumors of pediatric age and adulthood, respectively, share a common origin, both of them deriving from the neural crest cells. Although NB and MM have a different behavior, in respect to age of onset, primary tissue involvement and metastatic spread, the prognosis for high stage-affected patients is still poor, in spite of aggressive treatment strategies and the huge amount of new discovered biological knowledge. For these reasons researchers are continuously attempting to find out new treatment options, which in a near future could be translated to the clinical practice. In the last two decades, a strong effort has been spent in the field of translational research of immunotherapy which led to satisfactory results. Indeed, several immunotherapeutic clinical trials have been performed and some of them also resulted beneficial. Here, we summarize preclinical studies based on immunotherapeutic approaches applied in models of both NB and MM.",
keywords = "Adult, Animals, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Child, Clinical Trials as Topic, Disease Models, Animal, Drug Evaluation, Preclinical, Humans, Immunotherapy/methods, Melanoma/immunology, Neural Crest/pathology, Neuroblastoma/immunology, Remission Induction, Translational Medical Research",
author = "Fabio Morandi and Francesco Frassoni and Mirco Ponzoni and Chiara Brignole",
year = "2018",
doi = "10.1155/2018/8097398",
language = "English",
volume = "2018",
pages = "8097398",
journal = "Journal of Immunology Research",
issn = "2314-8861",
publisher = "Hindawi Limited",

}

TY - JOUR

T1 - Novel Immunotherapeutic Approaches for Neuroblastoma and Malignant Melanoma

AU - Morandi, Fabio

AU - Frassoni, Francesco

AU - Ponzoni, Mirco

AU - Brignole, Chiara

PY - 2018

Y1 - 2018

N2 - Neuroblastoma (NB) and malignant melanoma (MM), tumors of pediatric age and adulthood, respectively, share a common origin, both of them deriving from the neural crest cells. Although NB and MM have a different behavior, in respect to age of onset, primary tissue involvement and metastatic spread, the prognosis for high stage-affected patients is still poor, in spite of aggressive treatment strategies and the huge amount of new discovered biological knowledge. For these reasons researchers are continuously attempting to find out new treatment options, which in a near future could be translated to the clinical practice. In the last two decades, a strong effort has been spent in the field of translational research of immunotherapy which led to satisfactory results. Indeed, several immunotherapeutic clinical trials have been performed and some of them also resulted beneficial. Here, we summarize preclinical studies based on immunotherapeutic approaches applied in models of both NB and MM.

AB - Neuroblastoma (NB) and malignant melanoma (MM), tumors of pediatric age and adulthood, respectively, share a common origin, both of them deriving from the neural crest cells. Although NB and MM have a different behavior, in respect to age of onset, primary tissue involvement and metastatic spread, the prognosis for high stage-affected patients is still poor, in spite of aggressive treatment strategies and the huge amount of new discovered biological knowledge. For these reasons researchers are continuously attempting to find out new treatment options, which in a near future could be translated to the clinical practice. In the last two decades, a strong effort has been spent in the field of translational research of immunotherapy which led to satisfactory results. Indeed, several immunotherapeutic clinical trials have been performed and some of them also resulted beneficial. Here, we summarize preclinical studies based on immunotherapeutic approaches applied in models of both NB and MM.

KW - Adult

KW - Animals

KW - Antineoplastic Combined Chemotherapy Protocols/therapeutic use

KW - Child

KW - Clinical Trials as Topic

KW - Disease Models, Animal

KW - Drug Evaluation, Preclinical

KW - Humans

KW - Immunotherapy/methods

KW - Melanoma/immunology

KW - Neural Crest/pathology

KW - Neuroblastoma/immunology

KW - Remission Induction

KW - Translational Medical Research

U2 - 10.1155/2018/8097398

DO - 10.1155/2018/8097398

M3 - Review article

C2 - 30510968

VL - 2018

SP - 8097398

JO - Journal of Immunology Research

JF - Journal of Immunology Research

SN - 2314-8861

ER -